All In Biotech

Drug Trial Radar · NCT03353025

Study on Therapy of Non-invasive Prolactinoma

Prospective Randomized Clinical Study on Transsphenoidal or Dopamine Drugs Therapy Treat Non-invasive Prolactinoma

Last checked: Nov 20, 2026Latest source record: Nov 24, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 394 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

394

Planned (sponsor's estimate)

Start

Jan 1, 2016

Primary completion

Dec 31, 2025

Study completion Dec 31, 2025

Sponsor

Lead sponsor
First Affiliated Hospital, Sun Yat-Sen UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 24, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

the study aim to investigate the endocrine remission rate of non-invasive prolactinoma between transsphenoidal surgery treatment and Dopamine agonist treatment.

Conditions

  • Prolactinoma

Interventions

  • transsphenoidal surgery treatmentProcedure

    transsphenoidal surgery treatment

  • dopamine agonist treatmentDrug

    Minimum effective dose of dopamine agonist,bromocriptine,treat prolactinona

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Endocrine remission rateTime frame: five-year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-sen 5010 program

    Guangzhou, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.